ImaginAb Inc., an immuno-oncology imaging company, today announced that it has entered into a non-exclusive license and clinical trial collaboration with Nektar Therapeutics (Nasdaq: NKTR). Under the terms of the agreement, Nektar will use ImaginAb’s CD8 ImmunoPET technology to measure whole body and tumor CD8+ T cells’ density and distribution in cancer patients.
ImaginAb Inc., a clinical stage immuno-oncology imaging company, announced today the appointment of Friedhelm Blobel, Ph.D., former President and Chief Executive Officer of SciClone Pharmaceuticals, Inc. as an independent non-executive Director to its Board of Directors. In addition, Ivan Plavec, Ph.D., will be joining the company full time as Chief Business Officer (Dr. Plavec had up until now been serving in a consulting capacity).
ImaginAb Inc., an emerging immuno-oncology imaging company, today announced that it has entered into a multi-year, non-exclusive licensing collaboration with Merck, known as MSD outside the United States and Canada.
ImaginAb Inc., today announced the appointment of James Allison, Padmanee Sharma and Ramy Ibrahim to its Scientific Advisory Board (SAB) comprised of foremost global key opinion leaders in the development of anticancer therapies.
ImaginAb, Inc. announced today new directors of Japan KK, a wholly-owned subsidiary of Los Angeles-based ImaginAb, Inc. Headquartered in Tokyo, the subsidiary’s goal is to better realize partnering opportunities with Japanese pharmaceutical companies.